Recent advances in cancer immunotherapy—ranging from immune-checkpoint blockade
therapy to adoptive cellular therapy and vaccines—have revolutionized cancer treatment …

In the last decade, single-cell RNA sequencing routinely performed on large numbers of
single cells has greatly advanced our understanding of the underlying heterogeneity of …

Despite no apparent defects in T cell priming and recruitment to tumors, a large subset of T
cell rich tumors fail to respond to immune checkpoint blockade (ICB). We leveraged a …

Immunotherapy has been a remarkable clinical advancement in the treatment of cancer. T
cells are pivotal to the efficacy of current cancer immunotherapies, including immune …

CD8+ T cell responses are critical for anti-tumor immunity. While extensively profiled in the
tumor microenvironment, recent studies in mice identified responses in lymph nodes (LNs) …

The organization of immune cells in human tumors is not well understood. Immunogenic
tumors harbor spatially localized multicellular 'immunity hubs' defined by expression of the T …

The T cell receptor (TCR) complex is a naturally occurring antigen sensor that detects,
amplifies and coordinates cellular immune responses to epitopes derived from cell surface …

Adoptive cell transfer (ACT) with neoantigen-reactive T lymphocytes can mediate cancer
regression. Here we isolated unique, personalized, neoantigen-reactive T cell receptors …

Recent advances in neoantigen research have accelerated the development and regulatory
approval of tumor immunotherapies, including cancer vaccines, adoptive cell therapy and …

Circulating T cells from peripheral blood (PBL) can provide a rich and noninvasive source
for antitumor T cells. By single-cell transcriptomic profiling of 36 neoantigen-specific T cell …